Lilly's press release on retatrutide's pivotal Phase 3 obesity trial reports unprecedented weight reduction via triple agonism of GLP-1, GIP, and glucagon receptors, yet this RCT data remains preliminary and sponsor-controlled. Unlike the 2023 NEJM Phase 2 publication (n=338, double-blind, 48 weeks), the current trial lacks peer-reviewed scrutiny, raising risks of selective reporting on adverse events like gastrointestinal effects or muscle loss. Observational real-world data on tirzepatide (Jastreboff et al., NEJM 2022) already show 15-20% loss tapering at 72 weeks; retatrutide's glucagon component may amplify energy expenditure but introduces untested cardiovascular signals at scale. Original coverage missed population-level implications: if efficacy holds in diverse cohorts beyond trial exclusions, it could alter obesity's classification from behavioral to endocrine disorder, pressuring payers and guidelines. Conflicts of interest are clear—Lilly funds all stages—demanding independent meta-analyses before broad adoption.